Signatera Outperforms AMERK in Predicting Merkel Cell Carcinoma Recurrence, JAMA Study Shows
NTRA sits 99% above its 52-week low of $131.811.
Summary
A JAMA Dermatology study shows Natera's Signatera test significantly outperforms the AMERK antibody test in predicting Merkel cell carcinoma recurrence. Signatera achieved 90% sensitivity versus 55% for AMERK, with a median lead time of 5.1 months compared to 2.1 months. The test works across all patients regardless of viral status, unlike AMERK which is limited to virus-positive cases. This adds to a series of positive clinical validations and regulatory wins for Signatera, including recent FDA approval for bladder cancer and Japanese approval for colorectal cancer. The data strengthens Signatera's position in oncology monitoring and supports its inclusion in NCCN guidelines.
At the time of this announcement, NTRA was trading at $262.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $131.81 to $288.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.